Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Katerina Machova-Polakova"'
Autor:
Lenka Hovorkova, Lucie Winkowska, Justina Skorepova, Manuela Krumbholz, Adela Benesova, Vaclava Polivkova, Julia Alten, Michela Bardini, Claus Meyer, Rathana Kim, Toby N. Trahair, Emmanuelle Clappier, Sabina Chiaretti, Michelle Henderson, Rosemary Sutton, Lucie Sramkova, Jan Stary, Katerina Machova Polakova, Rolf Marschalek, Markus Metzler, Giovanni Cazzaniga, Gunnar Cario, Jan Trka, Marketa Zaliova, Jan Zuna
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-7 (2024)
Abstract Background The BCR::ABL1 is a hallmark of chronic myeloid leukemia (CML) and is also found in acute lymphoblastic leukemia (ALL). Most genomic breaks on the BCR side occur in two regions - Major and minor - leading to p210 and p190 fusion pr
Externí odkaz:
https://doaj.org/article/7d6bde3a548d4461bac54306fa7daa23
Autor:
Pavel Burda, Alzbeta Hlavackova, Vendula Polivkova, Nikola Curik, Adam Laznicka, Jitka Krizkova, Jiri Suttnar, Pavel Klener, Katerina Machova Polakova
Publikováno v:
Molecular Metabolism, Vol 88, Iss , Pp 102016- (2024)
Objective: A prominent, safe and efficient therapy for patients with chronic myeloid leukemia (CML) is inhibiting oncogenic protein BCR::ABL1 in a targeted manner with imatinib, a tyrosine kinase inhibitor. A substantial part of patients treated with
Externí odkaz:
https://doaj.org/article/5291343c15e94e9fb1424c43740d28fb
Autor:
Petra Belohlavkova, Daniela Zackova, Hana Klamova, Edgar Faber, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Ivana Jeziskova, Katerina Machova Polakova, Pavel Zak, Tereza Jurkova, Marika Chrapava, Jiri Mayer
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Background To evaluate the outcomes of first‐line imatinib versus nilotinib treatment for chronic myeloid leukemia in the chronic phase (CML‐CP) in real‐world clinical practice. Methods A propensity score analysis was performed to elim
Externí odkaz:
https://doaj.org/article/a3f1e095df1743329fc066dd5daac827
Autor:
Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Franck Emmanuel Nicolini, Henrik Hjorth-Hansen, Antonio Almeida, Jeroen J. W. M. Janssen, Jiri Mayer, Perttu Koskenvesa, Panayiotis Panayiotidis, Ulla Olsson-Strömberg, Joaquín Martinez-Lopez, Philippe Rousselot, Hanne Vestergaard, Hans Ehrencrona, Veli Kairisto, Katerina Machova Polakova, Satu Mustjoki, Marc Berger, Andreas Hochhaus, Markus Pfirrmann, Susanne Saussele
Publikováno v:
HemaSphere, Vol 7, p e0972454 (2023)
Externí odkaz:
https://doaj.org/article/a078e335813f413cb617882efe61628c
Autor:
Vaclava Polivkova, Stepan Hrabovsky, Zuzana Vrzalova, Jiri Stika, Jan Horacek, Pavla Pecherková, Hana Halamova, Jan Zuna, Jan Trka, Eva Fronkova, Marketa Zaliova, Michael Doubek, Katerina Machova Polakova, Cyril Salek
Publikováno v:
HemaSphere, Vol 7, p e851583f (2023)
Externí odkaz:
https://doaj.org/article/be19e96ecbdf4b32b21af17e6f53e7f1
Autor:
Lukas Semerad, Daniela Žáčková, Petra Belohlavkova, Jaroslava Voglova, Pavel Žák, Edgar Faber, Tomas Papajik, Ivana Skoumalova, Michal Karas, Pavel Jindra, Hana Klamová, Cyril Salek, Dana Srbová, Hana Zizkova, Lukas Stejskal, Olga Cerna, Eduard Cmunt, Petra Cicatkova, Anezka Kvetkova, Tomas Hornak, Ivana Jeziskova, Tomas Jurcek, Barbora Weinbergerová, Jirina Prochazkova, Katerina Machova Polakova, Adam Svobodnik, Radka Stepanova, Jiri Mayer
Publikováno v:
HemaSphere, Vol 7, p e70530bf (2023)
Externí odkaz:
https://doaj.org/article/e7c94ed4ac6546329523a51b5039e6a2
Autor:
Nikola Curik, Vaclava Polivkova, Pavel Burda, Jitka Koblihova, Adam Laznicka, Tomas Kalina, Veronika Kanderova, Jana Brezinova, Sarka Ransdorfova, Dominika Karasova, Katerina Rejlova, Marina Bakardjieva, Daniela Kuzilkova, David Kundrat, Jana Linhartova, Hana Klamova, Cyril Salek, Pavel Klener, Ondrej Hrusak, Katerina Machova Polakova
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Somatic mutations are a common molecular mechanism through which chronic myeloid leukemia (CML) cells acquire resistance to tyrosine kinase inhibitors (TKIs) therapy. While most of the mutations in the kinase domain of BCR-ABL1 can be successfully ma
Externí odkaz:
https://doaj.org/article/8005ecfc126d4bfeaf825124b03f64ae
Autor:
Monika Jaruskova, Nikola Curik, Rajna Hercog, Vaclava Polivkova, Eliska Motlova, Vladimir Benes, Hana Klamova, Pavla Pecherkova, Petra Belohlavkova, Filip Vrbacky, Katerina Machova Polakova
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 36, Iss 1, Pp 1-17 (2017)
Abstract Background Through high-throughput next-generation sequencing of promoters of solute carrier and ATP-binding cassette genes, which encode drug transporters, we aimed to identify SNPs associated with the response to imatinib administered for
Externí odkaz:
https://doaj.org/article/50d802bfd6834c5e9b0ebd9a761a70af
Autor:
Klara Srutova, Nikola Curik, Pavel Burda, Filipp Savvulidi, Giovannino Silvestri, Rossana Trotta, Hana Klamova, Pavla Pecherkova, Zofie Sovova, Jitka Koblihova, Tomas Stopka, Danilo Perrotti, Katerina Machova Polakova
Publikováno v:
Haematologica, Vol 103, Iss 12 (2018)
The fusion oncoprotein BCR-ABL1 exhibits aberrant tyrosine kinase activity and it has been proposed that it deregulates signaling networks involving both transcription factors and non-coding microRNAs that result in chronic myeloid leukemia (CML). Pr
Externí odkaz:
https://doaj.org/article/5a120df0b57040db90b998afc262735e
Autor:
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Alice FABARIUS, Hana Klamova, B Spieß, Cornelius Waller, Tim Bruemmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Satu Mustjoki, Edgar Faber, Jiri Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Janusz Kloczko, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois-Xavier Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
Membrane transporters are important determinants of drug bioavailability. Their expression and activity affect the intracellular drug concentration in leukemic cells impacting response to therapy. Pharmacogenomics represents genetic markers that refl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6488731f910555df7d7fa196a4610f36
https://doi.org/10.21203/rs.3.rs-2770615/v1
https://doi.org/10.21203/rs.3.rs-2770615/v1